Latest Schedule 13G passive stakes

Kamal Seyed Ghaffarian and X-Energy Holdings, LLC report significant beneficial ownership stakes in X-Energy, Inc. Class A Common Stock as of June 30, 2026.

Fuller & Thaler Asset Management, Inc. has disclosed a beneficial ownership of 5.19% of ICU Medical, Inc.'s common stock as of June 30, 2026.

Fuller & Thaler Asset Management, Inc. has reported beneficial ownership of 5.14% of Maximus, Inc.'s common stock as of June 30, 2026.

Fuller & Thaler Asset Management, Inc. has filed a Schedule 13G, reporting beneficial ownership of 4.94% of Greif, Inc. common stock as of June 30, 2026.

Fuller & Thaler Asset Management, Inc. has reported a beneficial ownership of 20,880,498.21 shares, representing 7.06% of the common stock of Graphic Packaging Holding Co.

OrbiMed Advisors LLC, OrbiMed Capital GP IX LLC, and OrbiMed Capital LLC have filed an amendment to their Schedule 13G, reporting beneficial ownership of Forte Biosciences, Inc. common stock.

Fuller & Thaler Asset Management, Inc. has filed an amendment to its Schedule 13G, reporting a minor beneficial ownership of Primoris Services Corp common stock.

Fuller & Thaler Asset Management, Inc. has reported a beneficial ownership of 16,708,253.67 shares, representing 4.69% of FNB Corp/PA's common stock, as of June 30, 2026.

Fuller & Thaler Asset Management, Inc. has disclosed a beneficial ownership of 5.03% in Collegium Pharmaceutical, Inc. common stock as of June 30, 2026.

Fuller & Thaler Asset Management, Inc. has reported an increased beneficial ownership of Beacon Financial Corp. common stock, now holding 4.7% of the class.

Corsair Capital and affiliated entities have reported beneficial ownership of 3.9% of Cineverse Corp.'s Class A Common Stock as of June 30, 2026.

Perceptive Advisors LLC, along with affiliated entities, has reported a beneficial ownership of 4.9% in Spyre Therapeutics, Inc., holding 4,319,496 shares.

Fuller & Thaler Asset Management, Inc. has reported a beneficial ownership of 6.99% in Science Applications International Corp. as of June 30, 2026.

Berto Acquisition Corp. II files Schedule 13G detailing significant beneficial ownership stakes held by Berto Acquisition Sponsor II LLC, Harry L. You, and Robert You.

NewHold Industrial Technology IV, LLC, along with managing members Kevin Charlton and Samy Hammad, have filed a Schedule 13G detailing their beneficial ownership of NewHold Investment Corp IV.

Decagon Asset Management LLP and Benjamin John Durham have reported beneficial ownership of 5.52% of Oaktree Acquisition Corp. III Life Sciences' Class A ordinary shares.

H/2 Credit Manager LP and H/2 Credit Manager GP LLC have filed an amended Schedule 13G, reporting 0.00 shares of Veris Residential, Inc. common stock beneficially owned.

Zippy, Inc. has disclosed beneficial ownership of 571,427 shares, representing 4.3% of Forum Markets Inc.'s common stock, as of April 20, 2026.

ADAR1 Capital Management, LLC, along with related entities and individuals, has filed a Schedule 13G amendment indicating a reduction in their beneficial ownership of Ovid Therapeutics Inc. common stock to below 5%.

Novo Holdings A/S has reported beneficial ownership of 9.0% of Hemab Therapeutics Holdings, Inc. common stock as of June 30, 2026.

Fund 1 Investments, LLC has reported beneficial ownership of 3,553,230 shares, representing 9.6% of the Class A Common Stock of 1-800 Flowers Com Inc.

Novo Holdings A/S has reported beneficial ownership of 3,883,289 shares, representing 8.8% of Avalyn Pharma Inc.'s common stock.

CastleKnight Master Fund LP and affiliated entities have filed an amendment to their Schedule 13G, reporting their beneficial ownership of Innventure, Inc. common stock.

Fund 1 Investments, LLC has reported acquiring a 5.49% stake in Genesco Inc., holding 609,963 shares of common stock.

Two Seas Capital LP, along with its general partner and chief investment officer, has disclosed a beneficial ownership of 8,377,636 shares, representing 5.4% of Sable Offshore Corp.'s common stock as of June 30, 2026.

Greenoaks LLC, along with its managing partners Neil Mehta and Benjamin Peretz, has reported beneficial ownership of 1,010,000 shares of Navan, Inc. Class A Common Stock, representing 0.42% of the class.

ADAR1 Capital Management, along with affiliates, has reported beneficial ownership of 9.9% of Grace Therapeutics, Inc. common stock, primarily through warrants.

Fund 1 Investments, LLC has reported a beneficial ownership of 422,467 shares, representing 4.23% of the outstanding common stock of WW International, Inc., as of June 30, 2026.

Multiple investment entities and individuals have filed a joint agreement regarding their beneficial ownership of Fervo Energy Company's Class A Common Stock.

ADAR1 Capital Management, LLC and related entities have filed a Schedule 13G amendment, reporting a reduction in their beneficial ownership of OnKure Therapeutics, Inc. Class A Common Stock.